On Demand Education

Integrating new technology into the management of non-dysplastic Barrett’s esophagus patients

Castle Biosciences hosted a case-based panel discussion at DDW 2023 highlighting how TissueCypher aids in the management of non-dysplastic Barrett’s esophagus patients.

Lipham J, Muthusamy R, Khara H

Individualized Risk Prediction in Barrett’s Esophagus

Jul 2016

Medical Laboratory Observer

Aaron DeWard

GNAQ and GNA11 mutations in uveal melanoma

Dec 2014

Melanoma Res 2014;24:525-34

Shoushtari AN and Carvajal RD

Genomic research in uveal melanoma

Retina Today 2010:67-9

Harbour JW

Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death

Oct 2004

Cancer Res 2004;64:7205-9

Onken MD, Worley LA, Ehlers JP, et al.

A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett’s Esophagus

Feb 2017

Rebecca J. Critchley-Thorne

A Tissue Systems Pathology Assay for High-Risk Barrett’s Esophagus

May 2016

Rebecca J. Critchley-Thorne

A Cost-Effectiveness Analysis of an Adenocarcinoma Risk Prediction Multi-Biomarker Assay for Patients with Barrett’s Esophagus

Oct 2019

Gene expression profiling in uveal melanoma: five-year prospective outcomes and meta-analysis

Jul 2020

Aaberg TM, Covington KR, Tsai T, et al

Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses.

Dec 2014

Aaberg TM, Cook RW, Oelschlager KM, et al.

Next-generation sequencing of uveal melanoma for detection of genetic alterations predicting metastasis.

Apr 2019

Afshar AR, Damato BE, Stewart JM, et al.

Gene Expression Profiling Prognostication of Posterior Uveal Melanoma: Does Size Matter?

Jan 2020

Binkley EM, Bena JF, Davanzo JM, Hinz C, Boldt HC, Singh AD